EBERTH Pharmaceuticals

Eberth Pharmaceuticals is a German specialty pharmaceutical company dedicated to the development and distribution of medicinal products for rare and orphan diseases. Based in Ursensollen, the company focuses on addressing unmet medical needs by optimizing existing active substances for specific patient populations, particularly in the field of pediatrics and metabolic disorders. Their most notable achievement is the development of Amglidia, the first oral suspension of glibenclamide specifically designed and approved for neonatal diabetes mellitus. Eberth Pharmaceuticals operates with a lean structure, leveraging strategic partnerships for manufacturing and global distribution while maintaining a strong focus on regulatory excellence and patient access. The company continues to evaluate niche therapeutic opportunities where specialized formulations can significantly improve clinical outcomes.